Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2026 04:00 ET | Source: Levicept

Levicept Announces The Lancet Publication of LEVI-04 Phase II Clinical Trial Results, Showing Significant Reduction in Pain and Symptoms of Osteoarthritis

Significant improvements in pain, function and patient global outcomes demonstratedLEVI-04 well tolerated and exhibits a favourable safety profile SANDWICH, United Kingdom, March 30, 2026 (GLOBE...
March 30, 2026 02:38 ET | Source: Trifork Group AG

22/2026・Trifork Group: Weekly report on share buyback

Schindellegi, Switzerland – 30 March 2026 Trifork Group AGCompany announcement no. 22/2026 Weekly report on share buyback On 27 February 2026, Trifork initiated a share buyback program in...
March 30, 2026 02:00 ET | Source: 4Bio Capital

4BIO Capital strengthens investment leadership with appointment of Therese Liechtenstein as Partner and Tetsu Maruyama as Venture Partner

Thera Liechtenstein brings extensive biotech investment and company‑building experience to new role as Partner at 4BIO CapitalTetsu Maruyama, former Head of Drug Discovery at Takeda Pharmaceuticals,...
March 28, 2026 15:00 ET | Source: MoonLake Immunotherapeutics AG

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated...
March 28, 2026 15:00 ET | Source: Roivant Sciences

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in...
March 28, 2026 11:00 ET | Source: Sanofi Winthrop Industrie

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed...
March 28, 2026 11:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and...
March 27, 2026 16:17 ET | Source: My Derma Dream

MyoGlow Analyzed: Why Is My Derma Dream MyoGlow Device Trending In The United States?

Miami, Florida, March 27, 2026 (GLOBE NEWSWIRE) -- The Arm Confidence Problem That Nobody Talks About There is a conversation happening in dressing rooms, group chats, and doctors' offices...
March 27, 2026 14:30 ET | Source: Hagens Berman Sobol Shapiro LLP

QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
March 27, 2026 14:14 ET | Source: Fisher House Foundation

Second Fisher House Under Construction at the Pittsburgh VA

Pittsburgh, PA, March 27, 2026 (GLOBE NEWSWIRE) -- Ground was broken today for a second Fisher House supporting the VA Pittsburgh Healthcare System in Pittsburgh, Pennsylvania, increasing capacity...